Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRO761 phase I/Ib study in MSI-high or dMMR advanced solid tumors
jRCT2031230088Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of HRO761 in Nonhematologic neoplasms and colorectal cancer (CRC) (3 arms), sponsored by Novartis. Primary endpoints: Safety and Tolerability. Started Jun 2023; status: active, not recruiting.
02
Drugs
HRO761
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031230088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230088.